BRAND NAME:

CEFTAVI

GENERIC NAME:

CEFTAZIDIME + AVIBACTAM

COMPOSITION

Ceftavi 2.5g Injection IV:

Each pack contains: Vial: Sterile Ceftazidime Pentahydrate/Sodium Carbonate eq. to Ceftazidime 2g Sterile Avibactam Sodium eq. to Avibactam 0.5g

DESCRIPTION

An antibacterial combination product consisting of the semisynthetic cephalosporin ceftazidime pentahydrate and the beta-lactamase inhibitor avibactam sodium for intravenous administration. Ceftazidime is a semisynthetic, third generation, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. Avibactam is reversible non-beta-lactam, beta lactamase

INDICATION

Complicated Intra-abdominal Infections (cIAI) In combination with metronidazole, It is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adult and pediatric patients (at least 3-week gestational age) caused by the following susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, and Pseudomonas aeruginosa.

Complicated Urinary Tract Infections (cUTI), including Pyelonephritis It is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in adult and pediatric patients (at least 3-week gestational age) caused by the following susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter freundii complex, Proteus mirabilis, and Pseudomonas aeruginosa.

Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) It is indicated for the treatment of hospital-acquired bacterial pneumonia adults and pediatric patients (at least 3 week gestational age) bacterial pneumonia (HABP/VABP) in 18 years or older caused by the following susceptible gram-negative microorganisms: Klebsiella pneumoniae,

Product Information Leaflets